Novartis' Cosentyx Boosted By High Psoriasis Skin Clearance Over 4 Years

Data showing Novartis' Cosentyx maintained high levels of skin clearance in psoriasis patients along with a favorable safety profile after four years should give the drug an advantage over new interleukin inhibitors undergoing Phase III trials in psoriasis.